<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Nature Network - pharma</title>
    <description>The latest taggings for pharma</description>
    <link>http://network.nature.com/announcements</link>
    <language>en-us</language>
    <ttl>40</ttl>
    <item>
      <title>Luc&#237;a de la Riva</title>
      <description>
        <![CDATA[Lucía de la Riva - ]]>
      </description>
    </item>
    <item>
      <title>Kamesh Janakiraman</title>
      <description>
        <![CDATA[Kamesh Janakiraman - ]]>
      </description>
    </item>
    <item>
      <title>It's the pipeline, stupid</title>
      <description>
        <![CDATA[Paul Smaglik - Jobs are getting tighter in biotech and pharma, according to a recent article in "Chemical & Engineering News":http://pubs.acs.org/cen/employment/86/8623employment.html. And the industry scene may worsen, with cutbacks and consolidations in a troubled economy. This week GSK "announced":http://www.usatoday.com/money/companies/management/2008-06-11-glaxo-rd-cuts_N.htm)it would cut 350 R&D]]>
      </description>
    </item>
    <item>
      <title>Feddback about Web 2.0 in pharma and biotech</title>
      <description>
        <![CDATA[Timo Hannay - After I asked him about Web 2.0 examples in pharma, Tim O'Reilly "Twittered":http://twitter.com/timoreilly/statuses/831541735 it. "Attila":http://network.nature.com/profile/UC5066B60 then wrote to point me to "this Nature Biotech editorial":http://dx.doi.org/10.1038/nbt0408-358 about the (supposedly) first biotech company blog. (Things have reached a sorry state when I]]>
      </description>
    </item>
    <item>
      <title>23 and Me</title>
      <description>
        <![CDATA[Timo Hannay - In response to my question about other organisations in pharma and biotech doing interesting things with Web 2.0 technologies, Tim O'Reilly suggests looking at "23 and Me":https://www.23andme.com/, who are "using web 2.0 principles to build a scientific data set". As]]>
      </description>
    </item>
    <item>
      <title>St Louis Biotech and Pharmaceutical Industry (STL- BP)</title>
      <description>
        <![CDATA[Fai Poon - This group is for people who are interested or involved in biotech, pharma industries at St Louis Area. It will be a good place to network, and updated about the new in STL area.]]>
      </description>
    </item>
    <item>
      <title>Big Cap Pharma is running out of Juice...</title>
      <description>
        <![CDATA[Fai Poon - Have you guys heard about this? All the big pharma's piplines are running dry. so, first question for discussion: Do you think so? After all, they are paying a lot of dope for scientist like me to be innovative. Why]]>
      </description>
    </item>
    <item>
      <title>Dosage (comic strip)</title>
      <description>
        <![CDATA[Viktor Poór - Life at the pharmaceutical industry...]]>
      </description>
    </item>
    <item>
      <title>The world without Prozac</title>
      <description>
        <![CDATA[Barbara Axt - Oh, the press... Scientists love to refer to "the media", "the press" and "the journalists" like an ubiquitous beast with a single mind and thousands of bodies, working together for the evil goal of misrepresenting science. (well, I think referring]]>
      </description>
    </item>
    <item>
      <title>Arrow Therapeutics: acquired but autonomous</title>
      <description>
        <![CDATA[Matt Brown - !http://farm2.static.flickr.com/1096/1201273271_e518b411b1.jpg?v=0! _Arrow HQ_ The acquisition of small, privately held specialist companies by big pharma is nothing new, but the large degree of independence "AstraZeneca":http://www.astrazeneca.com has granted its new subsidiary "Arrow Therapeutics":http://www.arrowt.co.uk follows a growing trend within mergers and acquisitions in]]>
      </description>
    </item>
  </channel>
</rss>
